The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis.

Nanoparticle-based drug delivery systems have considerable potential for treatment of tuberculosis (TB). The important technological advantages of nanoparticles used as drug carriers are high stability, high carrier capacity, feasibility of incorporation of both hydrophilic and hydrophobic substances, and feasibility of variable routes of administration, including oral application and inhalation. Nanoparticles can also be designed to allow controlled (sustained) drug release from the matrix. These properties of nanoparticles enable improvement of drug bioavailability and reduction of the dosing frequency, and may resolve the problem of nonadherence to prescribed therapy, which is one of the major obstacles in the control of TB epidemics. This article highlights some of the issues of nanotechnology relevant to the anti-TB drugs.

[1]  박태관.  Nanoparticles for Drug Delivery System , 2007 .

[2]  R. Pandey,et al.  Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. , 2005, Tuberculosis.

[3]  Gopal K. Khuller,et al.  Antitubercular inhaled therapy: opportunities, progress and challenges. , 2005, The Journal of antimicrobial chemotherapy.

[4]  Anjali Sharma,et al.  Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. , 2004, International journal of antimicrobial agents.

[5]  Anjali Sharma,et al.  Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. , 2004, The Journal of antimicrobial chemotherapy.

[6]  G. Khuller,et al.  Liposome technology for drug delivery against mycobacterial infections. , 2004, Current pharmaceutical design.

[7]  Barrett E. Rabinow,et al.  Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.

[8]  R. Pandey,et al.  Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. , 2004, The Journal of antimicrobial chemotherapy.

[9]  R. Müller,et al.  Solid lipid nanoparticles for parenteral drug delivery. , 2004, Advanced drug delivery reviews.

[10]  Michael Wirth,et al.  The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. , 2004, Advanced drug delivery reviews.

[11]  A. Florence.  Issues in Oral Nanoparticle Drug Carrier Uptake and Targeting , 2004, Journal of drug targeting.

[12]  Yu Zhang,et al.  Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. , 2004, International journal of pharmaceutics.

[13]  Rajesh Pandey,et al.  Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. , 2003, The Journal of antimicrobial chemotherapy.

[14]  S. Croft,et al.  Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs , 2003, Parasitology Research.

[15]  P. Couvreur,et al.  Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. , 2003, Advanced drug delivery reviews.

[16]  D A Weitz,et al.  Trojan particles: Large porous carriers of nanoparticles for drug delivery , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Garg,et al.  Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s). , 2002, International journal of pharmaceutics.

[18]  N Hussain,et al.  Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. , 2001, Advanced drug delivery reviews.

[19]  G. Khuller,et al.  Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles. , 2001, The Journal of antimicrobial chemotherapy.

[20]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[21]  A. R. Kulkarni,et al.  Biodegradable polymeric nanoparticles as drug delivery devices. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[22]  L. Heifets,et al.  Nanoparticles as Antituberculosis Drugs Carriers: Effect on Activity Against Mycobacterium tuberculosis in Human Monocyte-Derived Macrophages , 2000 .

[23]  R. Bodmeier,et al.  Incorporation of polymeric nanoparticles into solid dosage forms. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[24]  D. Quenelle,et al.  Use of Microsphere Technology for Targeted Delivery of Rifampin to Mycobacterium tuberculosis-Infected Macrophages , 1998, Antimicrobial Agents and Chemotherapy.

[25]  F. Bonini,et al.  Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: pharmacokinetics and in vitro antimicrobial activity , 1998 .

[26]  N. Düzgüneş,et al.  Liposome-encapsulated antibiotics. , 2005, Methods in enzymology.

[27]  Indu Bala,et al.  PLGA nanoparticles in drug delivery: the state of the art. , 2004, Critical reviews in therapeutic drug carrier systems.

[28]  P. Bummer,et al.  Physical chemical considerations of lipid-based oral drug delivery--solid lipid nanoparticles. , 2004, Critical reviews in therapeutic drug carrier systems.

[29]  R. Pandey,et al.  Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. , 2003, Tuberculosis.

[30]  Elias Fattal,et al.  Nanocapsule technology: a review. , 2002, Critical reviews in therapeutic drug carrier systems.

[31]  K Borner,et al.  Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. , 2000, The Journal of antimicrobial chemotherapy.

[32]  P. Couvreur,et al.  Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. , 2000, International journal of antimicrobial agents.